If you would like to submit a blog post for consideration, please email email@example.com
Cutaneous Lymphomas: New Therapies in Development
Modern therapies for cutaneous lymphomas were a topic of discussion at the European Academy of Dermatology and Venereology 2017 Congress, which was held in Geneva in September 2017.
Dr Emmanuella Guenova reviewed a number of new molecules in development, including:
This is a CD158K/KIR3DL2 inhibitor. It is a diagnostic and prognostic factor in cutaneous T cell lymphoma, and phase 1 trials have been completed showing some responses.
This is a CCR4 inhibitor and phase 2 trials have been completed. In published results from phases 1 and 2 trials, an overall response rate of 37 percent was found. The molecule is already approved in Japan for adult T cell leukaemia/lymphoma.
This is an anti-CD30 antibody. A phase 3 trial has been published with a 56.3 percent response rate. However, peripheral neuropathy was seen in 67 percent of patients and it was not always reversible.
Guenova, E. (September 2017.) Modern therapies for cutaneous lymphomas. 26th EADV Congress 2017 Conference Review. Research Review. Page 4.
Interested in skin cancer medicine?
The HealthCert Professional Diploma programs offer foundation to advanced training in skin cancer medicine, skin cancer surgery or dermoscopy and provide an essential step towards subspecialisation. All programs are university quality-assured, CPD-accredited and count towards multiple Master degree pathways and clinical attachment programs in Australia and overseas. The programs are delivered online and/or face-to-face across most major cities of Australia.